Administration of Erythropoietin to Patients with P-thalassemia Intermedia: a Preliminary Trial

ثبت نشده
چکیده

Patients with thalassemia major are considered to have high erythropoietin (Epo) activity.' However, Hammond et a1 reported that thalassemic patients had much less serum Epo activity compared with patients with hypoplastic anemia.* Determination of serum Epo levels in 32 patients from our clinic with homozygous p-thalassemia major and intermedia showed that Epo activity was not significantly higher than in normal controls except for the groups of minimally transfused infants who had higher levels, similar to those found in patients with severe aplastic anemia.3 A low serum Epo level for the degree of the anemia was also found in patients with sickle cell anemia.4 Recombinant human Epo (rhuEpo) has been shown to significantly increase red blood cells (RBCs), hemoglobin (Hb), and hematocrit (Hct) in patients with chronic renal failure, both in those who were maintained on hemodialysis and in those not requiring dialy~is.~ ' These observations may suggest that rhuEpo could be effective in patients with p-thalassemia intermedia and may result in an increase of 1 to 3 g of Hb, thus improving the quality of life without causing symptoms due to accelerated hematopoiesis. It is also possible that rhuEpo may specifically stimulate synthesis of fetal Hb (HbF).' Three patients with @-thalassemia intermedia were studied (two Arabs and a Kurdish Jew, Table 1). rhuEpo (EPREX) kindly supplied by Cilag AG International (SchafThausen, Switzerland) was administered in an initial dose of 1,000 Uikg intravenously twice daily, 1 day a week for 2 weeks. One hundred and ten days later, a second course of rhuEpo in a dose of 500 U k g was administered twice a week for 6 weeks and 1,000 U k g were administered twice a week for 3 more weeks (Fig 1). Globin chain

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

The effect of erythropoietin on blood parameters in thalassemia intermedia patients

Background: β-thalassemia is the most common hereditary disease in Iran, and more than 2 million carriers of β-thalassemia live in Iran. On the other hand, our country is located in the thalassemia belt, and no comprehensive study has been conducted regarding the effect of erythropoietin on blood parameters in thalassemia intermedia patients in our region. Therefore this study aimed to investig...

متن کامل

Administration of Erythropoietin to Patients with P-thalassemia Intermedia: a Preliminary Trial

Patients with thalassemia major are considered to have high erythropoietin (Epo) activity.' However, Hammond et a1 reported that thalassemic patients had much less serum Epo activity compared with patients with hypoplastic anemia.* Determination of serum Epo levels in 32 patients from our clinic with homozygous p-thalassemia major and intermedia showed that Epo activity was not significantly hi...

متن کامل

Administration of erythropoietin to patients with beta-thalassemia intermedia: a preliminary trial.

Patients with thalassemia major are considered to have high erythropoietin (Epo) activity.' However, Hammond et a1 reported that thalassemic patients had much less serum Epo activity compared with patients with hypoplastic anemia.* Determination of serum Epo levels in 32 patients from our clinic with homozygous p-thalassemia major and intermedia showed that Epo activity was not significantly hi...

متن کامل

Efficacy of High Dose Vitamin D on Pulmonary Artery Pressure in Thalassemia Patients Undergoing Blood Transfusion: A Randomized Trial

Background: Pulmonary arterial hypertension (PAH) may result in cardiomyopathy which is a major cause of death in thalassemia patients. Vitamin D is associated with benefits in cardiovascular disorders. Our purpose was to study effects of vitamin D on pulmonary artery pressure in thalassemia major and intermedia patients. Materials and Methods: This randomized trial was performed on 26 patient...

متن کامل

Comparison of Cardiac Function in Young Patients with Thalassemia Intermedia and Healthy Individuals Using Echocardiography Method

Background: Cardiac dysfunction due to chronic anemia and hemosiderosis are the major causes of death among patients with thalassemia intermedia. This study was performed to compare the cardiac function in thalassemia intermedia patients with normal subjects by means of echocardiography. Materials and Methods: This was a case-control study performed on 22 patients affected by thalassemia int...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2003